CLINICAL_TRIALS withdrawal · 2015-09-04

Clinical Trial Update: Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma [Phase 1, Phase 2]

This clinical trial update notes that the Phase 1/Phase 2 study of a stereotactic boost for oropharyngeal squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Dana-Farber Cancer Institute | Conditions: Squamous Cell Carcinoma of the Oropharynx | Phase 1, Phase 2 | Status: WITHDRAWN